Antileukotrienes in asthma: present situation (Q34240893)

31 July 2017

1 reference

title

Antileukotrienes in asthma: present situation (English)

1 reference

31 July 2017

0 references

L García-Marcos

1

1 reference

31 July 2017

A Schuster

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

2

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

441-466

1 reference

Leukotrienes and airway responses.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

New perspectives for asthma treatment: anti-leukotriene drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Effectiveness and tolerability of zafirlukast for the treatment of asthma in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

A drug interaction between zafirlukast and theophylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Lung function improvement in asthma with a cysteinylleukotriene receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Evening dosing is associated with higher plasma concentrations of pranlukast, a leukotriene receptor antagonist, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Effect of pranlukast, a leukotriene receptor antagonist, in patients with severe asthma refractory to corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Effect of multiple doses of montelukast, a CysLT1 receptor antagonist, on digoxin pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

Churg-Strauss syndrome associated with montelukast therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.441

21 January 2018

Identifiers

DOI

10.1517/14656566.2.3.441

1 reference

31 July 2017

1 reference